Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | MAOA | P21397 | 4/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30577139 | 1.00 | TDP1 (0.50) | TDP1CYP3A4MAOAMAOBHSP90AA1 | |
| SCHEMBL787009 | 1.00 | TDP1 (0.50) | TDP1CYP3A4MAOAMAOBHSP90AA1 | |
| SCHEMBL772678 | 0.86 | CYP3A4 (0.59) | TDP1CYP3A4MAOAMAOBCYP1A2 | |
| SCHEMBL9354434 | 0.80 | ALDH1A1 (0.58) | TDP1CYP3A4HSP90AA1CDK5CDK5R1 | |
| SCHEMBL10339388 | 0.80 | ALDH1A1 (0.58) | TDP1CYP3A4HSP90AA1CDK5CDK5R1 | |
| SCHEMBL3975452 | 0.79 | MAPT (0.56) | TDP1CYP3A4HSP90AA1CDK5CDK5R1 | |
| SCHEMBL3870583 | 0.78 | TDP1 (0.52) | TDP1CYP3A4MAOAMAOBCYP1A2 | |
| SCHEMBL441279 | 0.78 | TDP1 (0.47) | TDP1CYP3A4HSP90AA1CDK5CDK5R1 | |
| SCHEMBL24414604 | 0.77 | MAOA (0.50) | TDP1CYP3A4MAOAMAOBHSP90AA1 | |
| SCHEMBL421305 | 0.77 | CYP3A4 (0.50) | TDP1CYP3A4MAOAMAOBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205374-A1 | METHOD FOR PROVIDING A LABELED SINGLE ISOMERIC CHEMICAL ENTITY TARGETING VECTOR BASED ON THE USE OF AN ISOMER-FREE DIENOPHILE | UNIVERSITY OF COPENHAGEN (DK) | 2025-06-26 | — | — | US | disclosed |
| US-12281099-B2 | Isoindolinone substituted indoles and derivatives as RAS inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-04-22 | — | — | US | disclosed |
| EP-4520751-A1 | METHOD FOR RAPID OXIDATION OF DIHYDROPYRIDAZINES TO PYRIDAZINES | University of Copenhagen (DK) | 2025-03-12 | — | — | EP | disclosed |
| EP-4490136-A1 | METHOD FOR PROVIDING A LABELED SINGLE ISOMERIC CHEMICAL ENTITY TARGETING VECTOR BASED ON THE USE OF AN ISOMER-FREE DIENOPHILE | University of Copenhagen (DK) | 2025-01-15 | — | — | EP | disclosed |
| WO-2023170174-A1 | METHOD FOR PROVIDING A LABELED SINGLE ISOMERIC CHEMICAL ENTITY TARGETING VECTOR BASED ON THE USE OF AN ISOMER-FREE DIENOPHILE | UNIVERSITY OF COPENHAGEN (DK) | 2023-09-14 | — | — | WO | disclosed |
| EP-3931188-B1 | NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-08-30 | — | — | EP | disclosed |
| US-20220144810-A1 | NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-12 | — | — | US | disclosed |
| CN-113474340-A | Novel isoindolinone substituted indoles and derivatives as RAS inhibitors | 勃林格殷格翰国际有限公司 | 2021-10-01 | — | — | CN | disclosed |
| EP-2066673-B1 | TRICYCLIC COMPOUNDS AND ITS USE AS TYROSINE KINASE MODULATORS | CHEMBRIDGE CORP (US) | 2016-12-28 | — | — | EP | disclosed |
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-20100273763-A1 | ORGANOMETALLIC COMPLEXES AS THERAPEUTIC AGENTS | WOMEN & INFANTS HOSPITAL (US) | 2010-10-28 | — | — | US | disclosed |
| WO-2009117097-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE CORPORATION (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009117097-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE CORPORATION (US) | 2009-09-24 | — | — | WO | disclosed |
| EP-2066673-A2 | TRICYCLIC COMPOUNDS AND ITS USE AS TYROSINE KINASE MODULATORS | ChemBridge Research Laboratories, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-07-17 | — | — | US | disclosed |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-07-17 | — | — | US | disclosed |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-07-17 | — | — | US | disclosed |
| WO-2008070557-A2 | ORGANOMETALLIC COMPLEXES AS THERAPEUTIC AGENTS | WOMEN & INFANTS HOSPITAL (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008021369-A2 | TRICYCLIC COMPOUNDS AND ITS USE AS TYROSINE KINASE MODULATORS | CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021369-A2 | TRICYCLIC COMPOUNDS AND ITS USE AS TYROSINE KINASE MODULATORS | CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273763-A1 | ORGANOMETALLIC COMPLEXES AS THERAPEUTIC AGENTS | SCLY, SALL4, AS3MT | TDP1 3361/4885CYP3A4 1236/4885MAOA 2645/4885 |
| US-12281099-B2 | Isoindolinone substituted indoles and derivatives as RAS inhibitors | NRAS, KRAS, RASSF5 | TDP1 2732/4885CYP3A4 2714/4885MAOA 1723/4885 |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | MALT1, TPMT, TSLP | TDP1 376/4885CYP3A4 1201/4885MAOA 1818/4885 |
| US-20220144810-A1 | NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS | NRAS, RASSF5, KRAS | TDP1 2788/4885CYP3A4 2682/4885MAOA 2014/4885 |
| US-20250205374-A1 | METHOD FOR PROVIDING A LABELED SINGLE ISOMERIC CHEMICAL ENTITY TARGETING VECTOR BASED ON THE USE OF AN ISOMER-FREE DIENOPHILE | ALDH3A1, SQLE, DUOX1 | TDP1 2846/4885CYP3A4 544/4885MAOA 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.